Open Access Highly Accessed Open Badges Review

Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7 th2010"

Paolo A Ascierto1*, Eleonora De Maio1, Stefano Bertuzzi2, Giuseppe Palmieri3, Ruth Halaban4, Mary Hendrix5, Mohamed Kashani-sabet6, Soldano Ferrone7, Ena Wang8, Alistair Cochran9, Licia Rivoltini10, Peter P Lee11, Bernard A Fox1213, John M Kirkwood14, Claudio Dansky Ullmann15, Frederic F Lehmann16, Mario Sznol17, Douglas J Schwartzentruber18, Michele Maio19, Keith Flaherty20, Jerome Galon21, Antoni Ribas22, James Yang23, David F Stroncek8, Nicola Mozzillo1 and Franco M Marincola8

Author Affiliations

1 Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy

2 Office of the Director, Office of Science Policy Analysis, Office of Science Policy, National Institutes of Health, Bethesda, MD, USA

3 Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council (CNR), Sassari, Italy

4 Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA

5 Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

6 Center for Melanoma Research and Treatment, California Pacific Medical Center Research Institute, San Francisco, CA, USA

7 University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA

8 Infectious Diseases and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center and Center for Human Immunology (CHI), NIH, Bethesda, Maryland, USA

9 David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

10 Unit of Immunotherapy of Human Tumors, IRCCS Foundation, Istituto Nazionale Tumori, Milan, Italy

11 Department of Medicine, Stanford University, Stanford, CA, USA

12 Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, USA

13 Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon, USA

14 Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, and Melanoma Program, Pittsburgh Cancer Institute, Pittsburgh, PA, USA

15 Clinical Investigations Branch, Cancer Therapy Evaluation Program DCTD, National Cancer Institute, Bethesda, MD, USA

16 Cancer Immunotherapeutics Business Unit, GlaxoSmithKline Biologicals, Rixensart, Belgium

17 Yale Cancer Center, New Haven, CT, USA

18 Indiana University Health Goshen Center for Cancer Care, Goshen, IN, USA

19 Medical Oncology and Immunotherapy, Department of Oncology, University, Hospital of Siena, Istituto Toscano Tumori, Siena, Italy

20 Massachusetts General Hospital Cancer Center, Boston, MA, USA

21 Inserm Group Leader, Inserm U872, Team 15, Cordeliers Research Center, Paris, France

22 Department of Medicine, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA

23 Surgical Brach, NIH, Bethesda, MA, USA

For all author emails, please log on.

Journal of Translational Medicine 2011, 9:32  doi:10.1186/1479-5876-9-32

Published: 26 March 2011


Progress in understanding the molecular basis of melanoma has made possible the identification of molecular targets with important implications in clinical practice. In fact, new therapeutic approaches are emerging from basic science and it will be important to implement their rapid translation into clinical practice by active clinical investigation.

The first meeting of Melanoma Research: a bridge Naples-USA, organized by Paolo A. Ascierto (INT, Naples, Italy) and Francesco Marincola (NIH, Bethesda, USA) took place in Naples, on 6-7 December 2010.

This international congress gathered more than 30 international and Italian faculty members and was focused on recent advances in melanoma molecular biology, immunology and therapy, and created an interactive discussion across Institutions belonging to Government, Academy and Pharmaceutical Industry, in order to stimulate new approaches in basic, translational and clinical research. Four topics of discussion were identified: New pathways in Melanoma, Biomarkers, Clinical Trials and New Molecules and Strategies.